{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:20:03Z","timestamp":1769595603658,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T00:00:00Z","timestamp":1431302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T00:00:00Z","timestamp":1431302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1038\/bmt.2015.103","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T13:44:25Z","timestamp":1431351865000},"page":"1173-1179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?"],"prefix":"10.1038","volume":"50","author":[{"given":"M A","family":"Pulsipher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Langholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K R","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Bunin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Raetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R K","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gastier-Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Borowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S A","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,11]]},"reference":[{"key":"BFbmt2015103_CR1","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1016\/j.bbmt.2010.10.005","volume":"17","author":"MA Pulsipher","year":"2011","unstructured":"Pulsipher MA, Peters C, Pui CH . High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant 2011; 17: S137\u2013S148.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015103_CR2","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","volume":"120","author":"F Locatelli","year":"2012","unstructured":"Locatelli F, Schrappe M, Bernardo ME, Rutella S . How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012; 120: 2807\u20132816.","journal-title":"Blood"},{"key":"BFbmt2015103_CR3","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1182\/blood.V101.10.3835","volume":"101","author":"A Borgmann","year":"2003","unstructured":"Borgmann A, von Stackelberg A, Hartmann R, Ebell W, Klingebiel T, Peters C et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101: 3835\u20133839.","journal-title":"Blood"},{"key":"BFbmt2015103_CR4","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1038\/bmt.2008.58","volume":"41","author":"A Schrauder","year":"2008","unstructured":"Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C . Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant 2008; 41: S71\u2013S74.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015103_CR5","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2010","unstructured":"Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010; 376: 2009\u20132017.","journal-title":"Lancet"},{"key":"BFbmt2015103_CR6","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","volume":"26","author":"EA Raetz","year":"2008","unstructured":"Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ et al. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma. J Clin Oncol 2008; 26: 3971\u20133978.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015103_CR7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555\u2013562.","journal-title":"Blood"},{"key":"BFbmt2015103_CR8","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1182\/blood.V97.6.1572","volume":"97","author":"JJ Cornelissen","year":"2001","unstructured":"Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Lowenberg B et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572\u20131577.","journal-title":"Blood"},{"key":"BFbmt2015103_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/sj.bmt.1701064","volume":"21","author":"JR Passweg","year":"1998","unstructured":"Passweg JR, Tiberghien P, Cahn JY, Vowels MR, Camitta BM, Gale RP et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21: 153\u2013158.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015103_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.bbmt.2007.06.001","volume":"13","author":"S Lee","year":"2007","unstructured":"Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 1083\u20131094.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015103_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bbmt.2003.11.002","volume":"10","author":"A Nordlander","year":"2004","unstructured":"Nordlander A, Mattsson J, Ringden O, Leblanc K, Gustafsson B, Ljungman P et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2004; 10: 195\u2013203.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015103_CR12","first-page":"896","volume":"83","author":"P Zikos","year":"1998","unstructured":"Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Bregante S et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998; 83: 896\u2013903.","journal-title":"Haematologica"},{"key":"BFbmt2015103_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/sj.bmt.1703808","volume":"31","author":"A Gustafsson Jernberg","year":"2003","unstructured":"Gustafsson Jernberg A, Remberger M, Ringden O, Winiarski J . Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. Bone Marrow Transplant 2003; 31: 175\u2013181.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015103_CR14","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/sj.leu.2402690","volume":"16","author":"F Locatelli","year":"2002","unstructured":"Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Sacchi N et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002; 16: 2228\u20132237.","journal-title":"Leukemia"},{"key":"BFbmt2015103_CR15","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1182\/blood-2011-05-354233","volume":"118","author":"G Dini","year":"2011","unstructured":"Dini G, Zecca M, Balduzzi A, Messina C, Masetti R, Fagioli F et al. No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood 2011; 118: 6683\u20136690.","journal-title":"Blood"},{"key":"BFbmt2015103_CR16","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2008-02-137141","volume":"112","author":"DT Teachey","year":"2008","unstructured":"Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, Fish J et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 2008; 112: 2020\u20132023.","journal-title":"Blood"},{"key":"BFbmt2015103_CR17","doi-asserted-by":"publisher","first-page":"15113","DOI":"10.1073\/pnas.2436348100","volume":"100","author":"VI Brown","year":"2003","unstructured":"Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003; 100: 15113\u201315118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbmt2015103_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","volume":"107","author":"DT Teachey","year":"2006","unstructured":"Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006; 107: 1149\u20131155.","journal-title":"Blood"},{"key":"BFbmt2015103_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2141.2009.07889.x","volume":"147","author":"MA Pulsipher","year":"2009","unstructured":"Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P et al. A phase I\/II study of the safety and efficacy of the addition of sirolimus to tacrolimus\/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 2009; 147: 691\u2013699.","journal-title":"Br J Haematol"},{"key":"BFbmt2015103_CR20","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1182\/blood-2013-10-534297","volume":"123","author":"MA Pulsipher","year":"2014","unstructured":"Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL et al. The addition of sirolimus to tacrolimus\/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group\/Pediatric Blood and Marrow Transplant Consortium trial. Blood 2014; 123: 2017\u20132025.","journal-title":"Blood"},{"key":"BFbmt2015103_CR21","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood.V95.5.1572.005k12_1572_1579","volume":"95","author":"F Locatelli","year":"2000","unstructured":"Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572\u20131579.","journal-title":"Blood"},{"key":"BFbmt2015103_CR22","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1182\/blood-2013-10-534297","volume":"123","author":"MA Pulsipher","year":"2014","unstructured":"Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL et al. The addition of sirolimus to tacrolimus\/methotrexate GVHD prophylaxis in children with ALL: a phase III COG\/PBMTC trial. Blood 2014; 123: 2017\u20132025.","journal-title":"Blood"},{"key":"BFbmt2015103_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","volume":"27","author":"P Bader","year":"2009","unstructured":"Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27: 377\u2013384.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015103_CR24","first-page":"625","volume":"18","author":"MJ Borowitz","year":"2011","unstructured":"Borowitz MJ, Wood BL, Devidas M, Loh M, Raetz E, Nachman JB et al. Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute ymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. Blood 2011; 18: 625.","journal-title":"Blood"},{"key":"BFbmt2015103_CR25","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","volume":"99","author":"MN Dworzak","year":"2002","unstructured":"Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952\u20131958.","journal-title":"Blood"},{"key":"BFbmt2015103_CR26","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/sj.leu.2403001","volume":"17","author":"MJ Borowitz","year":"2003","unstructured":"Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia 2003; 17: 1566\u20131572.","journal-title":"Leukemia"},{"key":"BFbmt2015103_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbmt2015103_CR28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D Cox","year":"1972","unstructured":"Cox D . Regression models and life tables. J R Stat Soc B 1972; 34: 187\u2013202.","journal-title":"J R Stat Soc B"},{"key":"BFbmt2015103_CR29","first-page":"141","volume":"5","author":"O Aalen","year":"1978","unstructured":"Aalen O, Johansen S . An empirical transition matrix for nonhomogeneous Markov chains based on censored observations. Scand J Statist 1978; 5: 141\u2013150.","journal-title":"Scand J Statist"},{"key":"BFbmt2015103_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","volume":"33","author":"P Bader","year":"2015","unstructured":"Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 Trial. J Clin Oncol 2015; 33: 1275\u20131284.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015103_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/leu.2009.268","volume":"24","author":"M Bruggemann","year":"2010","unstructured":"Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521\u2013535.","journal-title":"Leukemia"},{"key":"BFbmt2015103_CR32","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012; 120: 5173\u20135180.","journal-title":"Blood"},{"key":"BFbmt2015103_CR33","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","volume":"30","author":"RJ Kreitman","year":"2012","unstructured":"Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30: 1822\u20131828.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015103_CR34","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","volume":"21","author":"JF Dijoseph","year":"2007","unstructured":"Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK . Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007; 21: 2240\u20132245.","journal-title":"Leukemia"},{"key":"BFbmt2015103_CR35","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493\u20132498.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015103_CR36","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.","journal-title":"Sci Transl Med"},{"key":"BFbmt2015103_CR37","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509\u20131518.","journal-title":"N Engl J Med"},{"key":"BFbmt2015103_CR38","first-page":"149","volume":"344","author":"SA Grupp","year":"2011","unstructured":"Grupp SA, June CH . Adoptive cellular therapy. Curr Top Microbiol Immunol 2011; 344: 149\u2013172.","journal-title":"Curr Top Microbiol Immunol"},{"key":"BFbmt2015103_CR39","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","volume":"22","author":"P Bader","year":"2004","unstructured":"Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696\u20131705.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015103_CR40","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/blood-2011-04-348805","volume":"118","author":"E Rettinger","year":"2011","unstructured":"Rettinger E, Willasch AM, Kreyenberg H, Borkhardt A, Holter W, Kremens B et al. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood 2011; 118: 5681\u20135688.","journal-title":"Blood"},{"key":"BFbmt2015103_CR41","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/leu.2010.133","volume":"24","author":"AC Lankester","year":"2010","unstructured":"Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 2010; 24: 1462\u20131469.","journal-title":"Leukemia"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015103","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T22:35:12Z","timestamp":1717886112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,11]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["BFbmt2015103"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.103","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,11]]},"assertion":[{"value":"17 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}